Shyam Lal Mudavath

Dr. Shyam Lal Mudavath

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SPShabi Parvez
Shabi Parvez
GYGanesh Yadagiri
Ganesh Yadagiri
MGMallikarjuna Rao Gedda
Mallikarjuna Rao Gedda
ASAakriti Singh
Aakriti Singh
OSOm Prakash Singh
Om Prakash Singh
SMShyam Lal Mudavath
Shyam Lal Mudavath
The development of an effective oral therapeutics is an immediate need for the control and elimination of visceral leishmaniasis (VL). We exemplify the preparation and optimization of 2-hydroxypropyl-β-cyclodextrin (HPCD) modified solid lipid nanoparticles (SLNs) based oral combinational cargo system of Amphotericin B (AmB) and Paromomycin (PM) against murine VL. The emulsion solvent evaporation method was employed to prepare HPCD modified dual drug-loaded solid lipid nanoparticles (m-DDSLNs). The optimized formulations have a mean particle size of 141 ± 3.2 nm, a polydispersity index of 0.248 ± 0.11 and entrapment efficiency for AmB and PM was found to be 96% and 90% respectively. The morphology of m-DDSLNs was confirmed by scanning electron microscopy and transmission electron microscopy. The developed formulations revealed a sustained drug release profile upto 57% (AmB) and 21.5% (PM) within 72 h and were stable at both 4 °C and 25 °C during short term stability studies performed for 2 months. Confocal laser scanning microscopy confirmed complete cellular internalization of SLNs within 24 h of incubation. In vitro cytotoxicity study against J774A.1 macrophage cells confirmed the safety and biocompatibility of the developed formulations. Further, m-DDSLNs did not induce any hepatic/renal toxicities in Swiss albino mice. The in vitro simulated study was performed to check the stability in simulated gastric fluids and simulated intestinal fluids and the release was found almost negligible. The in vitro anti-leishmanial activity of m-DDSLNs (1 µg/ml) has shown a maximum percentage of inhibition (96.22%) on intra-cellular amastigote growth of L. donovani. m-DDSLNs (20 mg/kg × 5 days, p.o.) has significantly (P < 0.01) reduced the liver parasite burden as compared to miltefosine (3 mg/kg × 5 days, p.o.) in L. donovani-infected BALB/c mice. This work suggests that the superiority of as-prepared m-DDSLNs as a promising approach towards the oral delivery of anti-leishmanial drugs.

1 December 2020 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
ASAakriti Singh
Aakriti Singh
GYGanesh Yadagiri
Ganesh Yadagiri
SPShabi Parvez
Shabi Parvez
OSOm Prakash Singh
Om Prakash Singh
AVAnurag Verma
Anurag Verma
SMShyam Lal Mudavath
Shyam Lal Mudavath

13 April 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
KAKanika Arora
Kanika Arora
PSP.M. Sherilraj
P.M. Sherilraj
KAK.A. Abutwaibe
K.A. Abutwaibe
BDBharti Dhruw
Bharti Dhruw
SMShyam Lal Mudavath
Shyam Lal Mudavath

1 April 2022 in Journal of Rare Earths
Verified
Journal Article
Closed access
PUPushpendra
Pushpendra
ISIndranil Suryawanshi
Indranil Suryawanshi
RKRimple Kalia
Rimple Kalia
RKRavi K. Kunchala
Ravi K. Kunchala
SMShyam Lal Mudavath
Shyam Lal Mudavath
BNBoddu S. Naidu
Boddu S. Naidu

3 November 2020 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Closed access
PDF file
MGMallikarjuna Rao Gedda
Mallikarjuna Rao Gedda
PMPrasoon Madhukar
Prasoon Madhukar
ASAshish Shukla
Ashish Shukla
SMShyam Lal Mudavath
Shyam Lal Mudavath
OSOnkar Nath Srivastava
Onkar Nath Srivastava
SSShyam Sundar
Shyam Sundar

1 March 2021 in Materials Today Communications
Verified
Journal Article
Closed access
PUPushpendra
Pushpendra
ISIndranil Suryawanshi
Indranil Suryawanshi
SSSaumya Srinidhi
Saumya Srinidhi
SSSarabjot Singh
Sarabjot Singh
RKRimple Kalia
Rimple Kalia
BNBoddu S. Naidu
Boddu S. Naidu